Catalent

Related Content

Catalent receives FDA approval as an additional manufacturing site for AveXis' Gene Therapy

Catalent adds potent manufacturing capabilities at its Buenos Aires site

Moderna and Catalent manufacture Moderna's COVID-19 vaccine candidate

Catalent completes purchase of pharmaceutical packaging facility in Japan

Catalent expands beauty and plant-based consumer health softgel capabilities in Canada and Brazil

Catalent acquires Japanese facility to provide local and global clinical supply solutions

Catalent partners with Humanigen to support FDA-approved Phase III Lenzilumab study for COVID-19

Catalent announces collaboration with Johnson & Johnson

Catalent Biologics completes $14m medicine packaging expansion

Catalent publishes fiscal 2019 Corporate Responsibility Report

Jobs and People

Catalent chooses new Chief Information Officer

Catalent announces next generation of cell and gene therapy leadership

Catalent CFO is inducted as a member of the Executive Leadership Council

Catalent strengthens biologics business with key senior appointments

Catalent creates new VP roles and fills in-house

Catalent appoints new German General Manager of clinical supply facility

Catalent appoints new PhD to the advisory board

Catalent appoints Ricardo Pravda to lead human resources function

Alessandro Maselli takes President and COO role at Catalent

Marlene Leuenberger joins Catalent

Similar Companies

Latest on Twitter

“This is a significant milestone for Catalent and the #genetherapy industry as a whole. Catalent is proud to be the first contract development and manufacturing organization to be approved for commercial gene therapy production.” https://t.co/niXGaCE9jy#drugsubstance #AAV

— Catalent Pharma (@CatalentPharma) August 13, 2020

@Moderna Inks $1.5B Contract with U.S. Govt. for COVID-19 Vaccine. The supply deal is for the initial 100 million doses of mRNA vaccine, and will be scaling up manufacturing capabilities. One of CDMO partners helping to scale is Catalent. https://t.co/HmbCBLgLSM

— Catalent Pharma (@CatalentPharma) August 13, 2020